千红制药：股东计划减持公司股份不超过2090万股

Group 1 - The core revenue composition of Qianhong Pharmaceutical for the year 2024 is 99.75% from the biopharmaceutical industry and 0.25% from other sources [1] Group 2 - Qianhong Pharmaceutical announced that major shareholder Zhao Gang and his concerted party plan to reduce their holdings by up to 20.9 million shares, which represents 1.63% of the total share capital [3] - The reduction will take place within three months after the announcement, starting 15 trading days from the disclosure date [3]